Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers--a first-time-in-human single ascending dose study.

[1]  R. Antonijoan,et al.  Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. , 2009, International journal of clinical pharmacology and therapeutics.

[2]  A. Blann,et al.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants , 2009, Vascular health and risk management.

[3]  V. Laux,et al.  Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra‐low‐molecular‐weight heparin, AVE5026 , 2009, Journal of thrombosis and haemostasis : JTH.

[4]  A. Turpie,et al.  AVE5026, a new hemisynthetic ultra‐low‐molecular‐weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose‐ranging study , 2009, Journal of thrombosis and haemostasis : JTH.

[5]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[6]  J. Martínez-González,et al.  Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism , 2008, Expert review of cardiovascular therapy.

[7]  G. Raskob,et al.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[8]  Elaine Gray,et al.  Heparin and low-molecular-weight heparin , 2008, Thrombosis and Haemostasis.

[9]  J. Fareed,et al.  Why differentiate low molecular weight heparins for venous thromboembolism? , 2007, Environmental health perspectives.

[10]  Scott R. Manalis,et al.  Monitoring of heparin and its low-molecular-weight analogs by silicon field effect , 2006, Proceedings of the National Academy of Sciences.

[11]  J. Hirsh,et al.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[12]  P. Walsh,et al.  The assembly of the factor X‐activating complex on activated human platelets , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  E. Racine.  Differentiation of the Low‐Molecular‐Weight Heparins , 2001, Pharmacotherapy.

[14]  R. Leadley.  Coagulation factor Xa inhibition: biological background and rationale. , 2001, Current topics in medicinal chemistry.

[15]  M. Prins,et al.  For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? , 2000, Thrombosis research.

[16]  J. Weitz.  Low-molecular-weight heparins. , 1997, The New England journal of medicine.

[17]  M. L. Larsen,et al.  Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). , 1978, Thrombosis research.

[18]  J. Fontcuberta,et al.  Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[19]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.